- General Drug Summary
- Description
- #39;s disease. [PubChem]
- Also Known As
- beta-Thiovaline; beta,beta-Dimethylcysteine; D-Mercaptovaline; D-Penamine; D-Penicilamine; D-Penicillamine; D-Penicyllamine; Dimethylcysteine; L-Penicillamine; Penicilamina [INN-Spanish]; Penicillamin; Penicillamina [DCIT]; Penicillaminum [INN-Latin]; Penicilllamine
- Structure
- Summary In Neonatal Jaundice
-
4 record(s) for Penicillamine Effective in Inducing Remission in Neonatal Jaundice.
- PMID
- Drug Name
- Efficacy
- Evidence
- 6892748
- Penicillamine
- Effective in Inducing Remission
- Clinical Trial
- Summary
- A drug used clinically for the treatment of neonatal hyperbilirubinaemia,and the doses of D-penicillamine used clinically cannot displace bilirubin from its binding to albumin.
- D-penicillamine, a non-bilirubin-displacing drug in neonatal jaundice. Acta paediatrica Scandinavica, 1980 Jan [Go to PubMed]
- D-penicillamine, a drug used clinically for the treatment of neonatal hyperbilirubinaemia, was tested for interference with the binding of bilirubin to human serum albumin by three methods: 1) The peroxidase technique, investigating the effect of D-penicillamine on the equilibrium concentration of unbound bilirubin in a solution containing a molar excess of albumin; 2) the MADDS method, measuring the concentration of vacant bilirubin binding site on albumin in a solution of pure albumin, or infant blood serum, with added D-penicillamine; and 3) injection of D-penicillamine into Gunn rats and determination of any decrease of plasma bilirubin which would be caused by displacement of the pigment. Results were negative in all cases. Quantitatively, the doses of D-penicillamine used clinically cannot displace bilirubin from its binding to albumin. The ameliorating effect on hyperbilirubinaemia in the newborn must be due to some other mechanism.
- 1036444
- Penicillamine
- Effective in Inducing Remission
- Clinical Trial
- Summary
- In preterm infants D-penicillamine treatment proved more effective than phototherapy deal with Neonatal jaundice.
- D-penicillamine therapy of neonatal jaundice: comparison with phototherapy. Acta paediatrica Academiae Scientiarum Hungaricae, 1976 [Go to PubMed]
- A total 330 newborns suffering from haemolytic disease of the newborn and hyperbilirubinaemia was treated with D-penicillamine. The therapy resulted in a significant decrease in the frequency of exchange transfusions and of high serum bilirubin levels among preterm and fullterm babies with or without sensitization. Concerning the drug's mechanism of action, reduction of the bilirubin level is achieved by means of the copper stored in the liver. The intravenous route is suggested for application of the drug. In preterm infants D-penicillamine treatment proved more effective than phototherapy.
- 665227
- Penicillamine
- Effective in Inducing Remission
- Clinical Trial
- Summary
- As compared to 41 infants of identical gestational age and treated under identical circumstances, penicillamine ensured favourable results, especially in babies born after the 33rd gestational week.
- D-penicillamine treatment of hyperbilirubinaemia in preterm infants. Acta paediatrica Academiae Scientiarum Hungaricae, 1978 [Go to PubMed]
- In 41 hyperbilirubinaemic infants born before the 38th gestational week intravenous D-penicillamine treatment was applied in doses of 300 mg/kg body weight/day. As compared to 41 infants of identical gestational age and treated under identical circumstances, penicillamine ensured favourable results, especially in babies born after the 33rd gestational week. Some undesirable side-effects have to be taken into account, but they are infrequent if the indication is correct.
- 12208095
- Penicillamine
- Effective in Inducing Remission
- Clinical Trial
- Summary
- pharmacological interventions to prevent hyperbilirubinaemia are utilized and the mainstay of treatment remains phototherapy. Previously studied pharmacological agents such as D-penicillamine, phenobarbital and clofibrate may yet prove useful.
- Pharmacological interventions for the treatment of neonatal jaundice. Seminars in neonatology : SN, 2002 Apr [Go to PubMed]
- In the neonate, hyperbilirubinaemia is usually due to a combination of an increased bilirubin load and decreased bilirubin elimination. Despite an understanding of the enzymatic pathways leading to bilirubin production and elimination, very few pharmacological interventions to prevent hyperbilirubinaemia are utilized and the mainstay of treatment remains phototherapy. Previously studied pharmacological agents such as D-penicillamine, phenobarbital and clofibrate may yet prove useful. Recent clinical trials using metalloporphyrins to inhibit heme catabolism and bilirubin production provides a novel pharmacological intervention for the treatment of neonatal jaundice. The safety and efficacy of these therapies will need to be confirmed prior to widespread use.